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ABSTRACT
Objectives: The prevalence of Huntington’s disease
(HD) recorded in the UK primary care records has
increased twofold between 1990 and 2010. This
investigation was undertaken to assess whether this
might be due to an increased incidence. We have also
undertaken a systematic review of published estimates
of the incidence of HD.
Setting: Incident patients with a new diagnosis of HD
were identified from the primary care records of the
Clinical Practice Research Datalink (CPRD). The
systematic review included all published estimates of
the incidence of HD in defined populations.
Participants: A total of 393 incident cases of HD
were identified from the CPRD database between 1990
and 2010 from a total population of 9 282 126
persons.
Primary and secondary outcome measures: The
incidence of HD per million person-years was
estimated. From the systematic review, the extent of
heterogeneity of published estimates of the incidence
of HD was examined using the I2 statistic.
Results: The data showed that the incidence of HD
has remained constant between 1990 and 2010 with
an overall rate of 7.2 (95% CI 6.5 to 7.9) per million
person-years. The systematic review identified 14
independent estimates of incidence with substantial
heterogeneity and consistently lower rates reported in
studies from East Asia compared with those from
Australia, North America and some—though not all—
those from Europe. Differences in incidence estimates
did not appear to be explained solely by differences in
case ascertainment or diagnostic methods.
Conclusions: The rise in the prevalence of diagnosed
HD in the UK, between 1990 and 2010, cannot be
attributed to an increase in incidence. Globally,
estimates of the incidence of HD show evidence of
substantial heterogeneity with consistently lower rates
in East Asia and parts of Europe. Modifiers may play
an important role in determining the vulnerability of
different populations to expansions of the HD allele.
Huntington’s disease (HD) is an autosomal-
dominant neurological disorder.1 2 Located
on chromosome 4p16.3, the normal form of
the gene contains up to 38 trinucleotide
repeats. The abnormal form of the gene has
from 40 to 125 trinucleotide repeats.3 The
HD gene codes for a protein called huntin-
tin. The abnormal form of the gene codes
for a toxic protein. The gene can expand
during transmission, possibly leading to dif-
ferent rates of incidence and prevalence in
different populations.
HD usually presents in early to middle life
with abnormal movements including chorea,
dystonia and rigidity.1 2 Patients may also
suffer severe psychiatric complications
including hallucinations, delusions, obsessive-
compulsive disorder, depression and bipolar
disorder.2 They contend with progressive cog-
nitive loss.1 2 It is uniformly fatal over a 10–
20-year decline. Aspiration pneumonia and
suicide are common causes of death.2
A previous study by us has shown4 that the
prevalence of HD, as diagnosed and
recorded in primary care records, has
increased from 5.4 (95% CI 3.8 to 7.5) per
100 000 in 1990 to 12.3 (95% CI 11.2 to
13.5) per 100 000 in 2010. In order to
explore the basis for this unexpected
ﬁnding, we have undertaken a study of the
incidence of HD in the UK over the same
time period.
To place our own ﬁndings in context we
have also undertaken a systematic review of
published estimates of the incidence of HD.
Strengths and limitations of this study
▪ The study provides the most reliable estimates of
the incidence of Huntington’s disease (HD), in
the UK, between 1990 and 2010.
▪ The study also provides a comprehensive and
contemporary review of the published incidence
of HD globally.
▪ The study of the incidence of HD in the UK relies
on new diagnoses of HD being reported in
primary care records.
▪ The systematic review does not attempt a quanti-
tative assessment of the quality of the included
studies.
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A previous systematic review of the incidence (as well as
prevalence) of HD was published in 20125 and identi-
ﬁed eight studies. That review only included studies
carried out between 1985 and 2010 on the grounds that
before 1985 MRI was not routinely in clinical use. Since
the diagnosis of symptomatic (manifest) HD is essen-
tially a clinical one, and not dependent on imaging, the
present review attempted to identify all published esti-
mates of the incidence of HD published between 1950
and 2014. We sought to examine the heterogeneity
between these estimates and, in particular, the extent to
which any observed differences between populations
might be explained by methods used for case ﬁnding
and diagnosis.
METHODS
UK population-based estimates of the incidence of HD
Study design and setting
The Clinical Practice Research Datalink (CPRD), for-
merly the General Practice Research Database (GPRD),
is a computerised database of anonymised longitudinal
medical records from primary care that has been col-
lected for over 25 years. The CPRD is assembled from
the electronic health records of patients registered with
around 625 contributing general practices and with over
5 million patients currently enrolled (representing
approximately 8% of the UK population). The practices
are broadly representative of those in the UK in geo-
graphical distribution, practice size, age and sex as well
as ethnicity and body mass index of registered patients.6
Each individual patient is assigned a unique identiﬁca-
tion number. No information from their medical
records, allowing identiﬁcation of individual patients, is
included in the database. The data are therefore entirely
anonymous to investigators. It is also important to appre-
ciate, for the beneﬁt of those unfamiliar with the UK’s
National Health Service, that patients requiring specialist
services must be referred by their general practitioner
(GP). The referring GP will invariably be informed of
the results of all investigations and the diagnosis.
CPRD includes the complete diagnostic and prescrib-
ing information for each registered patient. When
patients newly register with a contributing practice,
major past and existing diagnoses are recorded in their
medical records and are included in the research data-
base. However, the dates of onset and of past diagnoses
are not always accurately recorded. In particular, some
diagnoses that occurred in the past may be recorded
without a date or as occurring at, or shortly after, the
date of registration.
Morbidity in UK primary care is recorded using Read
codes Clinical Terms V.3.7 At both practice and individ-
ual patient levels, the data are subject to a range of
quality checks prior to being made available for research
purposes.8 The quality of the data has been found to be
high in a large number of independent validation
studies.9
The potential funders of the study played no part in
its design, analysis or interpretation.
Participants and variables
The source population was all patients aged 21 years or
more who were registered with general practices contrib-
uting to the CPRD between 1990 and 2010. The age of
21 was used to distinguish adult form of HD from the
very rare juvenile form of the condition.1 2 Eligible cases
were deﬁned as persons with one or more recorded
diagnoses of HD or Huntington’s chorea in their
medical records. The Read codes used to identify cases
of HD were F134.00 (Huntington’s chorea) and
Eu02200 (dementia in HD).
For each general practice record, the observation
period for the study began as the later of two dates:
either the study start date (1 January 1990) or the date
at which the practice started contributing research stand-
ard data to the CPRD. The end of the observation
period was the earlier of two dates: the last date for
which the practice contributed data to the CPRD, or the
study end date (31 December 2010). Individual patients
were included in denominators only during times within
the observation period that they were registered with a
practice contributing data to the GPRD and were aged
at least 21 years.
Incident patients were deﬁned as all those with a ﬁrst
record of an HD diagnostic code, during the observa-
tion period, but with two additional criteria. (1) The
patients’ ﬁrst recorded HD diagnosis was required to
have occurred at least 12 months after their ﬁrst entry in
the database. In other words, at least 12 months were
required to have elapsed since their registration date.
(2) Patients’ were required to have at least two recorded
contacts with their contributing practice prior to their
HD diagnosis. These additional criteria helped avoid
including prevalent cases as if they were incident ones.
Statistical methods
Incidence was calculated from the ratio of number of
persons with a new recorded diagnosis of HD for each
year from 1990 to 2010, divided by the total number of
persons in the database for that year, who had also had
at least 1 year in the database and were aged at least
21 years. Binomial CIs were calculated. In estimating the
incidence in age bands, annual incidence estimates were
averaged and approximate (binomial) 95% CIs calcu-
lated. All incidence rates are expressed per million
person-years.
Systematic review of studies of the incidence of HD
The criteria for inclusion in the systematic review were
that a study should be based on a deﬁned population
and that it should provide information about the
number of new HD diagnoses made within one or more
speciﬁc time frames. No study was excluded by virtue of
its date, the ages studied, or because of the approach
taken to either case ascertainment or the diagnosis of
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HD. The search dates covered the period January 1950
to December 2013. There were no language restrictions.
Relevant publications were sought as follows:
1. Search of MEDLINE and EMBASE (see web extra
annex 1). Studies fulﬁlling the inclusion criteria, but
published only as abstracts, were considered for
inclusion.
2. Scrutiny of the references quoted in reviews of the
epidemiology of HD.10–17
3. Examination of the reference lists in publications
meeting the inclusion criteria.
After the removal of duplicates, the full texts of the
remaining articles were examined. The relevant details
of those meeting the inclusion criteria were transcribed
independently (by ARW and MDR) and entered into
data extraction forms. Disagreements due to minor tran-
scription errors were resolved by consensus. The data
extraction forms recorded:
▸ The full reference;
▸ The geographical location and year(s) of the study;
▸ The relevant population size;
▸ The number of patient-years used in the estimation
(s) of incidence;
▸ The method(s) of case ascertainment;
▸ The method(s) of diagnosis;
▸ The number of new patients with HD during the year
(s) of study;
▸ The mean age at diagnosis, where provided, of
patients with HD together with the age range or the
95% CIs;
▸ The estimate(s) of incidence with (if calculated) their
95% CIs.
In some instances, where numerical data were lacking,
the number of patient-years was estimated by back
extrapolation. Where no 95% CIs were provided, these
were calculated from the available data. Reporting
follows, where appropriate, the PRISMA guidelines.18
Statistical methods
Incidence rates and their 95% CIs were recalculated
from the original reports from the number of new HD
diagnoses divided by the number of person-years. In
some instances, where either the number of cases or the
number of person-years was not quoted, these were esti-
mated by back extrapolation. The degree of heterogen-
eity was estimated from the I2 test.19
RESULTS
The incidence of adult HD in the UK
A total of 393 incident cases of HD were identiﬁed from
the CPRD database between 1990 and 2010 from a total
population of 9 282 126 persons (corresponding to
54 907 468 person-years). The incidence rates, in 5–
6-year bands (table 1), showed no signiﬁcant changes
between 1990 and 2010. The apparent ﬂuctuations
between 1990 and 1994 (see web extra annex 2) are
likely to be due to sampling error as both the number of
incident cases, and the denominators, were relatively
small during these years. The average incidence rate of
HD, during the entire period, was 7.2 (95% CI 6.5 to
7.9) per million patient-years. Rates for females (7.1,
95% CI 6.1 to 8.10) and males (7.3, 95% CI 6.3 to 8.4)
were similar.
The mean age at diagnosis was 52.4 years (SD 15.1;
IQR 42–64 years; see ﬁgure 1). It was almost identical in
females (mean 52.4; SD 15.2; IQR 42–64 years) and
males (52.4; SD 15.1; IQR 41–64 years). The ages of
onset are shown in table 1 and do not show any signiﬁ-
cant change over the period of the study. The average
annual incidence rates in relation to the age of onset
are shown in table 2.
Systematic review of the incidence of HD
The numbers of studies initially identiﬁed, screened,
subjected to full-text review and included in the ﬁnal
synthesis are shown schematically in ﬁgure 1. Additional
details of the included and excluded in studies are avail-
able in the web extra tables 2–5. We identiﬁed 14 pub-
lished studies (ﬁgure 1) which, together with the results
of the present study, provided 15 investigations into the
incidence of HD for inclusion in our systematic review
(table 3).
Estimates of the incidence of HD (table 3) ranged
from 0 (95% CI 0 to 97.0)20 to 8.0 (95% CI 2.0 to 23) per
million person-years,21 although the latter study was con-
ducted among a restricted age range (45–64 years). It is
clear from this table that there is marked heterogeneity
(I2=98.5%, 95% CI 98.2% to 98.6%) across studies, even
after the omission of the two age-speciﬁc estimates.21 22
Lower estimates of incidence were consistently reported
for studies conducted in the East Asia region including
Guam,20 Hong Kong23 and Taiwan24 compared with most
of those undertaken in Europe, North America and
Australia. There is, though, heterogeneity between
Table 1 Average incidence rates and age of onset of HD 1990–2010
Years
Incident
cases
Denominators
(patient years)
Incidence per million
patient years (95% CIs)
Mean age of onset
in years (SD and IQR)
1990–1996 56 6 778 613 8.26 (6.24 to 10.73) 51.5 (13.9 40 to 61)
1997–2003 138 18 533 173 7.45 (6.26 to 8.80) 53.1 (13.7 44 to 64)
2004–2010 199 29 522 583 6.7 (5.84 to 7.75) 52.1 (16.4 40 to 65)
HD, Huntington’s disease.
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European estimates of incidence. Studies conducted in
Finland,25 Iceland26 and the Ferrara region of Italy27
show incidence estimates of around one per million
person-years or less. Other studies carried out in UK,21 28
as well as the results reported here, suggest incidence
rates of around 7–8 per million patient years (table 4).
Estimates undertaken in Greece,29 the Basque region of
Spain,30 Australia31 and North America32 33 are compar-
able to those in the UK including the present study. The
low incidence of the juvenile form of HD,22 in the UK, is
to be expected in the light of the known low prevalence
of this very rare form of HD.
The approaches used in case ascertainment, and the
criteria for accepting a diagnosis of HD among the
included studies, are shown in table 4. A variety of
methods were used in identifying patients with HD and,
to a lesser extent, in the diagnostic criteria each study
adopted. However, this variability is inadequate to
explain the marked differences in the heterogeneity of
incidence worldwide.
DISCUSSION
UK estimate of incidence
The absence of any consistent change in the incidence
of HD in the UK, between 1990 and 2010, is in marked
contrast to the substantial increase in the prevalence of
HD over the same period. Evans et al4 offered a number
of possible explanations for the apparent rise in preva-
lence. These included (1) an increase in incidence; (2)
an increase in the diagnosis of HD as a result of the
availability of a genetic test permitting physicians to diag-
nose HD in patients with atypical symptoms; (3) an
increase in the willingness of GPs to record a diagnosis
of HD in patients’ records; (4) or an increase in the lon-
gevity of those with manifest HD as a consequence of
the general population trend as well as the result of
better symptomatic treatment.
Using the same database and during the same time
period, our present study shows that the increase in
prevalence of HD previously reported4 does not appear
to be explained by a rise in incidence. More reliable
diagnoses of HD are also unlikely to be an explanation
because, if this had been the case, we should have
observed an apparent increase in incidence. It is pos-
sible that patients with a prior diagnosis of HD are more
likely to register with a practice contributing to the
CPRD. We doubt that this is a viable explanation and,
anyway, it should also be reﬂected by an increased
incidence.
There are two remaining possibilities for this surpris-
ing rise in prevalence in the face of a constant inci-
dence: (1) GPs are now more willing to include an HD
diagnosis in the records of previously diagnosed patients
potentially due to a decline in the stigma associated with
the condition34; (2) survival has markedly improved. We
are currently examining this second possibility.
Systematic review of incidence
The present systematic review conﬁrms the apparent het-
erogeneity of the incidence of HD between different
populations.5 Studies undertaken in Eastern Asia show
consistently lower estimates of incidence compared with
those reported from Australasia, North America and
parts of Europe. It is notable, however, that substantial
heterogeneity in the incidence of HD has been reported
in the European region with, as already discussed, esti-
mates from Finland, Iceland and Northern Italy being
substantially less than those reported in Spain and the
UK (table 3).
Although it is possible that this observed heterogeneity
in the estimates of the incidence of HD could be due to
differences in the methodology of case ascertainment
and diagnosis, examination of the data in table 4 sug-
gests that this is unlikely to be the sole explanation.
Indeed, the heterogeneity of the estimates of the
Figure 1 Flow diagram of search strategy.
Table 2 Incidence and age of onset
Incidence per million patient years (95% CIs)
Age of onset (years) 1990–1996 1997–2003 2004–2010
<40 7.9 (4.4 to 13.1) 5.6 (3.7 to 8.1) 6.6 (4.9 to 8.7)
40–49 13.2 (7.0 to 22.6) 11.8 (8.0 to 16.8) 10.8 (8.0 to 14.3)
50–59 14.8 (7.6, 25.8) 13.1 (9.0 to 18.4) 7.2 (4.8 to 10.4)
>60 10.0 (5.7 to 16.2) 10.7 (7.8 to 14.3) 10.3 (8.1 to 13.0)
4 Wexler NS, et al. BMJ Open 2016;6:e009070. doi:10.1136/bmjopen-2015-009070
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Table 3 Incidence studies from the systematic review
Study ID Location
Study year
(s)
Incident
cases Patient-years
Incidence per 1 000 000
person-years (95% CIs) Age of onset Comments
Eastern Asia
Chen 196820 Guam 1960–1966 0 265 825 0.00 (0 to 13.9) Not stated
Chang 199423 Hong Kong,
China
1984–1991 20 43 520 000 0.46 (0.28 to 0.71)* 37.6 (range 20–52)
Chen 201024 Taiwan 2000–2007 165 15 900 000 1.04 (0.89 to 1.21) Not stated Average incidence
between 2000 and
2007
Australasia
McCusker 200031 NSW, Australia 1991 and
1996
1991=26
1996=39
1991=5 732 031
1996=6 038 969
1991=4.5 (3.0 to 6.7)
1996=6.5 (4.6 to 8.8)
47.9
(SD 13.7)
Europe
Palo 198725 Finland 1980s 2† 4 900 000 0.2 to 0.4 (0.02 to 1.3)* Not stated
Govoni 198827 Ferrara, Italy 1971–1987 14 6 032 096‡ 1.1 (0.4 to 2.3) Not stated
Ramos-Arroyo 200530 Navara and
Basque, Spain
1994–2002 111 21 165 000 4.7 (4.5 to 6.3)* 43.7
(SD 15)
Mercy 200821 Cambridge UK 2000–2006 9 453 600 8.0 (2.0 to 23) Not stated Restricted age range
(45–64 years)
Panas 201129 Greece 1995–2008 48† 10 964 020 4.38 (3.23 to 5.50) 44.0 (SD 12.9)
Sackley 201128 UK 2004–2008 85 14 713 708 5.71 (4.45 to 7.07) 48.3 (SD14.) Average incidence
between 2004 and
2008
Sveinsson 201226 Iceland 1988–2007 8 5 714 285‡ 1.4 (0.6 to 2.8)* 51 (range 28–68)
Douglas 201322 UK 1990–2010 12 17 142 857 0.70 (0.36 to 1.22) Median=15 (range
5–20)
Restricted to juvenile
HD
Current study UK 1990–2010 393 54 907 468 7.2 (6.5 to 7.9) 52 years (SD 16) Also includes annual
incidence rates1990–
2010
North America
Kokman 199432 Minnesota, USA 1950–1989 10 4 134 000‡ Definite=3.0 (1.0 to 5.0)
Definite+probability=5.0
(3.0 to 9.0)
Not stated .
Almqvist 200133 British
Columbia,
Canada
1996–1999 110 16 058 394‡ 6.9 (5.7 to 8.3)* 46.9 (SD 13.7) Author states
population is
‘approximate’
*95% CIs not included in the published report but estimated for this review.
†Numbers of patients with HD calculated by back extrapolation.
‡Patient-years calculated by back extrapolation.
HD, Huntington’s disease; NSW, New South Wales.
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Table 4 Sources of cases and diagnostic criteria used in the included studies
Study ID Location Source of cases Diagnostic criteria
Asia
Chen 196820 Guam Records of patients attending the
Guam Memorial Hospital
Not stated
Chang 199423 Hong Kong,
China
Computer search of all major
hospitals. Announcement in Hong
Kong Medical Association Newsletter
asking for information about known or
suspected cases. Enquiry of all
neurologists and psychiatrists in Hong
Kong
All patients examined by a neurologist
plus a psychiatrist. Diagnosis based on
positive family history plus insidious
progressive disorder with chorea,
cognitive impairment and often
psychiatric disturbance. Positive CT
scan with caudate atrophy considered
to be ‘supportive’ of an HD diagnosis
Chen 201024 Taiwan Outpatient and inpatient claims from
the National Health Insurance
Research Database
Search of National Health Insurance
Research Database for ICD-9 code
333.4
Australasia
McCusker 200031 NSW,
Australia
Records of the NSW HD Service.
Records of the major general and
chronic psychiatric hospitals in NSW.
Questionnaires to adult and paediatric
neurologists, psychiatrists, genetic
counsellors and clinical geneticists
Definite: chorea or ataxia with a
positive family history or expanded
CAG repeat
Europe
Palo 198725 Finland Systematic search of all university,
central, general and central psychiatric
hospitals
Not stated
Govoni 198827 Ferrara, Italy Records of the neurology clinics of
Ferrera and Bologna, civil records,
records of the psychiatric institutions,
records of public and private geriatric
nursing homes
Combination of a positive family
history, choreiform movements, mental
deterioration
Ramos-Arroyo 200530 Navara and
Basque, Spain
Referrals to the Medical Genetics
Laboratory of the Hospital Virgen del
Camino, Pamplona, Spain, for
diagnostic testing for HD between
1993 and 2002. Also searched for
additional patients from the Basque
country who might have been referred
to other HD diagnostic genetic centres
in Spain. In addition, patients who
underwent presymptomatic testing and
became symptomatic within the study
period were also included
Definite=typical clinical features plus
<36 CAG repeats plus positive family
history
Suspect=without positive family history
Mercy 200821 Cambridge
UK
Attendees/referrals to Addenbrooks’
Hospital memory/early dementia clinic
UHDRS >5
Panas 201129 Greece Records of the Laboratory of
Neurogenetics, Athens (the only
neurogenetics lab in Greece)
Neurological examination including the
UHDRS plus CAG repeat length in a
subset of patients
Sackley 201128 UK Using THIN primary care research
database the authors identified Read
codes for HD
Based on recorded diagnosis
Sveinsson 201226 Iceland Medical records and hospital
discharge diagnoses of all hospitals
including records of neurological,
psychiatric and genetic departments.
Information from practising
neurologists and selected GPs.
Information from family members
Hyperkinetic movement disorder plus
psychiatric symptoms plus progressive
cognitive decline plus a positive family
history or positive DNA analysis
Continued
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incidence of HD is broadly consistent with the hetero-
geneity of estimates of the prevalence of the condition.
Lower prevalence rates of HD have been noted in
studies carried out in Asia compared with those among
populations predominantly of European decent. The
estimates of incidence among Finish and Icelandic
peoples as well as Italians from the Ferrara region of
Italy are also compatible with the low prevalence rates in
these populations. The very low incidence of juvenile
HD, in the UK22 (0.70, 95% CI 0.36 to 1.22 per million
person-years), is also consistent with its low prevalence
(6.77, 95%CI 5.6 to 8.12 per million) compared with the
most recent (2010) estimate of the prevalence of adult
HD (123, 95% CI 112 to 135 per million).4
A deﬁnitive molecular genetic test for the HD muta-
tion has been available since the early 1990s in most
developed countries. Differences in the rates of genetic
testing might provide some explanation for the differ-
ences in the heterogeneity of estimates of incidence in
the populations studied. This explanation also seems
unlikely. For example, the overall incidence of HD in
Taiwan, during the past decade, has remained consist-
ently lower than estimates from the UK over similar time
periods.
The present study suggests that, over the past two
decades, the incidence of HD in the UK has remained
constant despite a doubling of the prevalence of HD
during this same time period. We also demonstrate that
there is signiﬁcant heterogeneity in the estimates of the
incidence of HD carried out in other populations world-
wide. Particularly low estimates of incidence in Eastern
Asia, as well as parts of Europe, suggests that modiﬁers
of the expression of the disease may play an important
role in determining the propensity of populations to be
vulnerable to expansions of the HD allele.3 35 36 Better
understanding of the potential modiﬁers of expression,
in different populations, may help to develop new thera-
peutic strategies.
Author affiliations
1Department of Neurology and Psychiatry, Columbia University, New York,
New York, USA
2Hereditary Disease Foundation, New York, New York, USA
3Department of Medical Statistics, London School of Hygiene and Tropical
Medicine, London, UK
4Department of Non-Communicable Disease Epidemiology, London School of
Hygiene and Tropical Medicine, London, UK
5Department of Neurodegenerative Diseases, Institute of Neurology, University
College London, London, UK
Contributors All the authors contributed to the design of the study. Data
extraction from CPRD was undertaken by LC, ID, SJE and LS. Data analyses
were performed by LC, NSW and MDR. Statistical analyses were performed by
LC, SJE and MDR. The systematic review was undertaken by ARW and MDR.
All authors contributed to, and approved, the submitted manuscript.
Funding The authors gratefully acknowledge support for this study from the
Hereditary Disease Foundation, the Wellcome Trust and the Medical Research
Council.
Competing interests None declared.
Ethics approval The study was approved from the CPRD’s Independent
Scientific Advisory Committee and from the London School of Hygiene and
Tropical Medicine’s Research Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/
REFERENCES
1. Novak MJ, Tabrizi SJ. Huntington’s disease. BMJ 2010;341:34–40.
2. Wexler NS. Huntington’s disease: advocacy driving science. Annu
Rev Med 2012;63:1–22.
Table 4 Continued
Study ID Location Source of cases Diagnostic criteria
Douglas 201322 UK Primary care National Health Service
electronic health records
As recorded in patients’ electronic
health records (Read codes F134.00
and Eu2200)
Current study UK Primary care National Health Service
electronic health records
As recorded in patients’ electronic
health records (Read codes F134.00
and Eu2200)
North America
Kokman 199432 Minnesota,
USA
Scrutiny of records of hospitals,
nursing homes, private practitioners,
state psychiatric hospital
Definite HD=documented record of
progressive choreiform movement
disorder; evidence of autosomal
dominant inheritance; progressive
cognitive, behavioural, and/or
emotional dysfunction. Probable HD=2
out of 3 of the above criteria
Almqvist 200133 British
Columbia,
Canada
Patients referred to Medical Genetics
Laboratory/HD clinic
Patients with signs and symptoms
compatible with HD and with CAG
repeat lengths >36
HD, Huntington’s disease; GP, general practitioner; ICD, International Classification of Diseases; NSW, New South Wales; THIN, The Health
Improvement Network; UHDRS, United Huntington’s Disease Rating Scale.
Wexler NS, et al. BMJ Open 2016;6:e009070. doi:10.1136/bmjopen-2015-009070 7
Open Access
group.bmj.com on March 9, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
3. [No authors listed]. A novel gene containing a trinucleotide repeat
that is expanded and unstable on Huntington’s disease
chromosomes. The Huntington’s disease Collaborative Research
Group. Cell 1993;72:971–83.
4. Evans SJW, Douglas I, Rawlins MD, et al. Prevalence of adult
Huntington’s disease in the UK based on diagnoses recorded in
general practice records. J Neurol Neurosurg Psychiatry
2013;84:1156–60. doi:10.1136/jnnp-2012-304636
5. Pringsheim T, Wiltshire K, Day L, et al. The incidence and
prevalence of Huntington’s disease: a systematic review and
meta-analysis. Mov Disord 2012;27:1083–91.
6. Herrett E, Gallagher AM, Bhashkaran K, et al. Data resource profile:
Clinical Practice Research Datalink (CPRD). Int J Epidemiol
2015;4:827–36.
7. NHS Connecting for Health. Read Codes. http://www.
connectingforhealth.nhs.uk/systemsandservices/data/uktc/readcodes
(accessed 9 Jun 2015).
8. Clinical Practice Research Datalink. CPRD Governance. http://www.
cprd.com/governance/ (accessed 9 Jun 2015).
9. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity
of diagnoses in the General Practice Research Database:
a systematic review. Br J Clin Pharmacol 2010;69:4–14.
10. Conneally PM. Huntington’s disease: genetics and epidemiology.
Am J Hum Genet 1984;36:506–26.
11. Harper PS. The epidemiology of Huntington’s disease. Hum Genet
1992;89:365–76.
12. Kay C, Fisher E, Hayden MR. Epidemiology. In: Bates GP, Tabrizi
SJ, Jones L, eds. Huntington’s disease. 4th edn. Oxford: Oxford
University Press, 2014:131–64.
13. Leung CM, Chan YW, Chang CM, et al. Huntington’s disease in
Chinese: a hypothesis of its origin. J Neurol Neurosurg Psychiatr
1992;55:681–4.
14. Al-Jader LN, Harper PS, Krawczak M, et al. The frequency of
inherited disorders database: prevalence of Huntington disease.
Community Genet 2001;4:148–57.
15. Hoppitt T, Pall H, Calvert M, et al. A systematic review of the
incidence and prevalence of long-term neurological conditions in the
UK. Neuroepidemiology 2011;36:19–28.
16. Centre for Molecular Medicine and Therapeutics. Published reports
of the worldwide prevalence of Huntington’s disease. University of
British Columbia, 2011.
17. http://www.cmmt.ubc.ca/research/diseases/huntingtons/HD_
Prevalence (accessed 9 Jun 2015).
18. Moher D, Liberati A, Tetzlaff J, et al., The PRISMA Group. Preferred
Reporting Items for Systematic Reviews and Meta-Analyses: the
PRISMA statement. PLoS Med 2009;6:e1000097.
19. Higgins JP, Thompson SG, Deeks JJ, et al.
Measuring inconsistency in meta-analysis. BMJ 2003;
327:557–60.
20. Chen KM, Brody JA, Kurland LT. Patterns of neurologic diseases on
Guam. Arch Neurol 1968;19:573–8.
21. Mercy L, Hodges JR, Dawson K, et al. Incidence of early-onset
dementias in Cambridgeshire, United Kingdom. Neurology
2008;71:1496–9.
22. Douglas I, Evans S, Rawlins MD, et al. Juvenile Huntington’s
disease: a population-based study using the General Practice
Research Database. BMJ Open 2013;3:e002085.
23. Chang CM, Yu YL, Fong KY, et al. Huntington’s disease in Hong
Kong Chinese: epidemiology and clinical picture. Clin Exp Neurol
1994;31:43–51.
24. Chen YY, Lai CH. Nationwide population-based epidemiologic study
of Huntington’s disease in Taiwan. Neuroepidemiology
2010;35:250–4.
25. Palo J, Somer H, Ikonen E. Low prevalence of Huntington’s disease
in Finland. Lancet 1987;2:805–6.
26. Sveinsson O, Halldórsson S, Olafsson E. An unusually low
prevalence of Huntington’s disease in Iceland. Eur Neurol
2012;68:48–51.
27. Govoni V, Pavoni M, Granieri E, et al. La chorea de Huntington nella
provinica di Ferrara negli anni 1971–1987. Studio descrittivo. Riv
Neurol 1988;58:235–40.
28. Sackley C, Hoppitt TJ, Calvert M, et al. Huntington’s disease:
current epidemiology and pharmacological management in UK
primary care. Neuroepidemiology 2011;37:216–21.
29. Panas M, Karadima G, Vassos E, et al. Huntington’s disease in
Greece: the experience of 14 years. Clin Genet 2011;80:586–90.
30. Ramos-Arroyo MA, Moreno S, Valiente A. Incidence and mutation
rates of Huntington’s disease in Spain: experience of 9 years of
direct genetic testing. J Neurol Neurosurg Psychiatry
2005;76:337–42.
31. McCusker EA, Casse RF, Graham SJ, et al. Prevalence of
Huntington disease in New South Wales in 1996. Med J Aust
2000;173:187–90.
32. Kokmen E, Ozekmekci FS, Beard CM, et al. Incidence and
prevalence of Huntington’s disease in Olmsted County, Minnesota
(1950 through 1989). Arch Neurol 1994;51:696–8.
33. Almqvist EW, Elterman DS, MacLeod PM, et al. High incidence rate
and absent family histories in one quarter of patients newly
diagnosed with Huntington disease in British Columbia. Clin Genet
2001;60:198–205.
34. Wexler AR. The woman who walked into the sea: Huntington’s and
the making of a genetic disease. New Haven: Yale University Press,
2008.
35. Warby SC, Visscher H, Collins JA, et al. HTT haplotypes contribute
to differences in Huntington disease prevalence between Europe
and East Asia. Eur J Hum Genet 2011;19:561–6.
36. Xu M, Wu ZY. Huntington disease in Asia. Chin Med J (Engl)
2015;128:1815–19.
8 Wexler NS, et al. BMJ Open 2016;6:e009070. doi:10.1136/bmjopen-2015-009070
Open Access
group.bmj.com on March 9, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
systematic review
UK: a UK-based primary care study and a 
Incidence of adult Huntington's disease in the
J Tabrizi, Ian Douglas, Liam Smeeth and Stephen J Evans
Nancy S Wexler, Laura Collett, Alice R Wexler, Michael D Rawlins, Sarah
doi: 10.1136/bmjopen-2015-009070
2016 6: BMJ Open 
 http://bmjopen.bmj.com/content/6/2/e009070
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/6/2/e009070
This article cites 30 articles, 5 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (282)Neurology
 (83)Genetics and genomics
 (1424)Epidemiology
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on March 9, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
